Acadia Pharmaceuticals Announces Commercial Leadership Change
28 January 2021 - 8:05AM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
Michael Yang, Executive Vice President and Chief Commercial
Officer, will be leaving the organization effective January 29,
2021 to assume the role of chief executive officer at another
healthcare company. Charmaine Lykins, Senior Vice President, Global
Product Planning and Chief Marketing Officer and Amanda Morgan,
Senior Vice President, Chief Revenue and Customer Officer, will
lead the commercial organization.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210127005903/en/
Charmaine Lykins, Senior Vice President,
Global Product Planning and Chief Marketing Officer (Photo:
Business Wire)
“On behalf of the entire management team and our employees, I
want to thank Michael for his significant contributions and we wish
him well in his future endeavors,” said Steve Davis, Chief
Executive Officer. “Amanda and Charmaine have been the foundation
of our commercial success and I look forward to their continued
leadership.”
Charmaine Lykins, Senior Vice President, Global Product
Planning and Chief Marketing Officer
Charmaine Lykins is Senior Vice President, Global Product
Planning and Chief Marketing Officer and leads Acadia’s healthcare
professional and consumer marketing, marketing operations and new
product planning functions. She joined the company in 2018 as Vice
President, Marketing and in 2019 was promoted to Senior Vice
President and became a member of the company’s Executive Management
Committee.
Ms. Lykins has over 25 years of global experience
commercializing healthcare brands, including 10 product launches
representing first-in-class therapies for central nervous system
disorders. She led the U.S. launch teams for REXULTI® in depression
and schizophrenia, prelaunch readiness for ABILIFY MAINTENA® in
bipolar disorder, and ZIPSOR® for acute pain. Ms. Lykins also led
commercial launch strategies for LATUDA® in bipolar depression and
schizophrenia, CYMBALTA® for depression and diabetic neuropathic
pain, and ZYPREXA® for bipolar depression and treatment resistant
depression in combination with fluoxetine.
Prior to joining Acadia, Ms. Lykins served as Global Vice
President of Marketing at Lundbeck. Prior to Lundbeck she held
global marketing leadership roles at Sunovion and U.S. marketing
and sales leadership roles at Eli Lilly. Her career experience
includes strategic commercialization roles in Europe, Asia, and the
Middle East, as well as in research and development.
Ms. Lykins has an MBA with an emphasis in international business
from the Darla Moore School of Business at University of South
Carolina, and bachelor’s degrees in chemistry and honors humanities
from Ball State University.
Amanda Morgan, Senior Vice President, Chief Revenue and
Customer Officer
Amanda Morgan is Senior Vice President, Chief Revenue and
Customer Officer and leads Acadia’s neuroscience, long-term care,
national accounts, and health systems. She joined the company in
2017 as Vice President, Sales and Market Access and in 2019 was
promoted to Senior Vice President and became a member of the
company’s Executive Management Committee.
Ms. Morgan has over 20 years of experience in developing
high-performing cultures and teams in the healthcare industry.
Prior to joining Acadia, she was the U.S. Head of Patient Services
at Baxalta where she was responsible for launching the patient
services organization that supported more than $6 billion dollars
in revenue. Prior to Baxalta, she was U.S. Area Vice President at
Baxter leading the hospital and healthcare sales teams overseeing
market expansion, supplemental indications, and new product launch
strategies.
Throughout her career, Ms. Morgan has held leadership roles with
increasing responsibility in marketing, sales, market access,
patient services and operations in multiple therapeutic areas. She
has a strong track record of executing commercial strategies in
neuroscience, immunology, hematology, and oncology, as well as in
rare diseases.
Ms. Morgan earned her Bachelor of Science degree in Business
Administration, Marketing from The University of Iowa.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our late-stage development efforts
are focused on dementia-related psychosis, negative symptoms of
schizophrenia and Rett syndrome, and in early-stage clinical
research we are exploring novel approaches to pain management, and
cognition and neuropsychiatric symptoms in central nervous system
disorders. For more information, visit us at www.acadia-pharm.com
and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210127005903/en/
Media Contact: Acadia Pharmaceuticals Inc. Eric Endicott (858)
914-7161 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2024 to May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2023 to May 2024